Kalvista Pharmaceuticals Inc (KALV) is a Healthcare · Biotechnology company listed on NASDAQ. Price $27.00 (+0.04%), Market cap $1.43B, 52-week low–high $10.76 ~ $26.81.
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
Financial statements, price targets, institutional (13F) holdings and related news for Kalvista Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Kalvista Pharmaceuticals Inc trades at $27.00 (+0.04%). Real-time quotes and charts are available on BlackAll Trade.
Kalvista Pharmaceuticals Inc has a market cap of about $1.43B.
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inh